Geneva – The Medicines Patent Pool (MPP) has just opened a call for expression of interest (EoI) inviting interested manufacturers to take up a sublicence for the hepatitis treatment glecaprevir/pibrentasvir (G/P). Reinforcing the recognition of hepatitis C and powering the fight against the disease, the EoI comes in at the same time as the announcement of this year’s Nobel Prize for the discovery of hepatitis C to Harvey J. Alter, Michael Houghton & Charles M. Rice.

G/P is one of the three hepatitis C treatments recommended by the World Health Organization (WHO). This oral, one-pill-a-day treatment:

  • Is pan-genotypic and can be used across all six hepatitis C virus (HCV) genotypes.
  • Is the first-line treatment for non-cirrhotic patients with a treatment course of only eight weeks.
  • Is indicated for use in HCV patients with any degree of renal impairment, including patients on dialysis.
  • Is currently being studied for its paediatric use and could soon be available for treating children from age of three in a lower dose formulation.

Globally, 71 million people[1] are currently living with chronic HCV, many of them in LMICs.  “Antiviral medicines can cure over 95% of people[2] with hepatitis C infection, so we need to have quality treatments affordable and available,” said Charles Gore, MPP’s Executive Director, “G/P offers unique advantages to key populations such as those with kidney damage, so it is important to have this treatment option readily available”.

This EoI is MPP’s second call. The first call was launched in 2019, and resulted in Mylan being granted a sublicence for G/P.

AbbVie granted MPP a royalty-free licence in November 2018 that enables quality-assured manufacturers to develop and sell generic medicines containing G/P in 96 low- and middle-income countries (LMICs) at affordable prices.

The agreement allows sublicensees to develop, make, have made, use, file for regulatory approval, sell, import and export G/P for treatment of HCV as per the agreement.
The full text of the agreement can be found here.

MPP invites EoI from potential sublicensees based anywhere in the covered territory and in India to manufacture and sell glecaprevir/pibrentasvir (G/P).

All users, including old users will need to create an account in our new portal.
Submission deadline: 31 October 2020
For any questions regarding the EOI Portal or the G/P application, please email